Treatment for Atrial Fibrillation with Rapid Ventricular Response

Immediate Assessment and Rate Control

For hemodynamically stable patients with atrial fibrillation (AF) and rapid ventricular response (RVR), the American College of Cardiology recommends intravenous beta-blockers (metoprolol, esmolol) or non-dihydropyridine calcium channel blockers (diltiazem, verapamil) as first-line agents for acute rate control, with diltiazem achieving rate control faster than metoprolol 1
Hemodynamic instability includes severe hypotension, ongoing myocardial ischemia/angina, acute heart failure, or shock, and requires immediate direct-current cardioversion without delay for pharmacological therapy, according to the American College of Cardiology 1, 2, 3
The American College of Cardiology states that cardioversion is a Class I recommendation (strongest evidence) for hemodynamically unstable patients 1, 2, 4

Beta-blockers are preferred in patients with myocardial ischemia or acute myocardial infarction (MI), coronary artery disease, hyperthyroidism, or preserved left ventricular function (LVEF >40%), as recommended by the American College of Cardiology 2, 3, 6
The American College of Cardiology recommends dosing for beta-blockers as follows: metoprolol 2.5-5 mg IV bolus over 2 minutes, up to 3 doses, esmolol 500 mcg/kg IV bolus over 1 minute, then 50-300 mcg/kg/min infusion, and propranolol 1 mg IV over 1 minute, up to 3 doses at 2-minute intervals 1
Non-dihydropyridine calcium channel blockers are preferred in patients with bronchospastic lung disease (asthma, COPD) where beta-blockers are contraindicated, or preserved LVEF without decompensated heart failure, according to the American College of Cardiology 1, 2

The American College of Cardiology recommends intravenous amiodarone or digoxin for acute rate control in patients with heart failure, with amiodarone dosing at 150 mg IV over 10 minutes (or 300 mg over 1 hour), then 0.5-1 mg/min (or 10-50 mg/h) continuous infusion 1, 3, 7
Beta-blockers and calcium channel blockers are contraindicated (Class III: Harm) in decompensated heart failure or cardiogenic shock, as stated by the American College of Cardiology 1, 2, 7
The American College of Cardiology recommends intravenous procainamide as the drug of choice (Class I recommendation) for AF with pre-excitation, with alternative agents including ibutilide and flecainide (Class IIa-IIb) 3, 6

The American College of Cardiology states that anticoagulation must be initiated as soon as possible and continued for at least 4 weeks after cardioversion unless contraindicated, with options including IV heparin, LMWH, or factor Xa/direct thrombin inhibitor 1
Long-term anticoagulation decisions should be based on the CHA₂DS₂-VASc score regardless of rate control strategy, as recommended by the American College of Cardiology 5

The American College of Cardiology recommends that when pharmacological rate control fails, AV node ablation with ventricular pacing is reasonable, but should not be performed without prior attempts at medical rate control (Class III: Harm) 1, 2, 5